Drugs / L-778,123
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00004057 | Dec 1998 → Dec 2000 | cancer of unknown primary site, lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00003430 | Apr 1998 → Apr 2000 | head and neck cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-778,123 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004057 ↗ |
| Modality | Small molecule | — CHEMBL279433 ↗ |
| Route | Intravenous | “Patients receive paclitaxel IV over 3 hours followed within 24 hours by L-778,123 IV over 7 days.” NCT00004057 ↗ |